Granules India Limited · NSE:GRANULES
Granules India — Q2 FY19 Earnings Presentation
22 slides from Granules India's earnings presentation, Oct 30, 2018
Slide 1: Exchange filing cover letter
@ GRANULES REGISTERED OFFICE GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081, Telangana, INDlAl Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granu|esindia,com, www.granulesindia.com CIN: L24110T61991PLC012471 Dated October 30, 2018 To, National Stock Exchang
Slide 2: Investor Presentation Q2 FY19
Investor Presentation Q2 FY19 © 2018 Granules India Limited., All Rights Reserved.
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Q2 FY19 Updates
Q2 FY19 Updates 3 © 2018 Granules India Limited., All Rights 3 Reserved.
Slide 5: Q2 Financial Performance Highlights
Q2 Financial Performance Highlights S A L E S F R O M O P E R AT I O N S EBITDA PAT EPS* Rs 581 Crs Rs 105 Crs Rs 60 Crs Rs 9.5 48% over Q2FY18 25% over Q2FY18 49% over Q2FY18 35% over Q2FY18* * Diluted Q2 EPS annualised Product Vertical wise – Q2FY19 Molecule wise – Q2FY19 Geography wise – Q2FY19 P
Slide 6: Q2 Balance Sheet Highlights
Q2 Balance Sheet Highlights Net Debt to EBITDA Return on Equity 16% 3.0 12% 2.4 Mar-18 Sep-18 Mar-18 Sep-18 Asset Turnover (x) Cash to Cash Cycle (Days) 1.6 140 137 1.5 Mar-18 Sep-18 Mar-18 Sep-18 © 2018 Granules India Limited., All Rights Reserved. 5
Slide 7: Key Highlights for Q2FY19
Key Highlights for Q2FY19 48% growth in topline on a year on year basis driven by API and FD sales Net Profit grew by 49% to INR 60 Crs JVs reported a combined profit of INR 13 Crs Successfully passed on the higher raw material prices to majority of our customers GPI successfully launched
Slide 8: About Granules
About Granules 7 © 2018 Granules India Limited., All Rights 7 Reserved.
Slide 9: Granules at a Glance
Granules at a Glance Building Blocks Installed Capacity Regulatory Approvals Business Divisions Global Reach Regulatory Compliance 34,560 TPA of API USFDA, EDQM, EU Core Business 60+ countries Operational Efficiency 285 KL GMP, COFEPRIS, WHO Emerging Business 250+ customers 4,800
Slide 10: Group Structure and Manufacturing Presence
Group Structure and Manufacturing Presence Incorporated in 1991, this is the only listed entity in the group, with 4 operational plants located in Hyderabad Granules India (Jeedimetla, Bonthapally and Gagillapur) and 1 in Vizag Pharma City 1 Granules USA Inc. 100% subsidiary, for front-end marketing
Slide 11: Business Structure – Granules India
Business Structure – Granules India Focus on core products including Auxiliary growth engine to secure the Paracetamol, Metformin HCl, Ibuprofen, future while strengthening the core Guaifenesin and Methocarbamol. Added business Cetrizine and Fexofenadine to the portfolio Growth avenue for diff
Slide 12: Core Business
Core Business Overview Drivers Value Enablers Present across the entire pharmaceutical One of the World’s largest PFI and single site FD facility manufacturing value chain from API to API capacity 34,560 MT, PFI 24,400 TPA & Finished Finished Dosages. Dosages 18 billion Scale DMFs, Dossiers,
Slide 13: Emerging Business: Multi APIs / Onco
Emerging Business: Multi APIs / Onco Overview Drivers Value Enablers Addition of USFDA approved multiproduct manufacturing site enabling scale-up and Multiproduct facility with an installed capacity of 285KL manufacturing of niche APIs through in- Integrated API to FD facility for Oncology hou
Slide 14: US Generics
US Generics Overview Drivers Value Enablers Fully integrated infrastructure from R&D, “Niche products,” hidden opportunities with different manufacturing to marketing enabling layers of complexities “Make in America” Differentiated dosage forms; limited competition Portfolio Complex generics
Slide 15: JVs – Granules Omnichem & Granules Biocause
JVs – Granules Omichem & Granules Biocause Granules Omnichem Overview Drivers Value Enablers 2,500 25% 19.5% 19.1% Granules Biocause, a venture with China High margin opportunity in 2,000 20% based Hubei Biocause operational since CRAMS with manufacturing for 2007. Objective is to enable core in
Slide 16: Core Management Team
Core Management Team Mr. C. Krishna Prasad Mr. Prasad is the Founder of Granules and has three decades of experience in the pharmaceutical industry. In 1984, he set up a Paracetamol manufacturing facility, focused on capital and process efficiency. Pharmaceutical Formulations Intermediates Chairman
Slide 17: Financial Performance
Financial Performance 16 © 2018 Granules India Limited., All Rights 16 Reserved.
Slide 18: Consolidated Metrics
Consolidated Metrics Product Vertical wise - FY18 Molecule wise - FY18 Geography wise - FY18 14% 14% 14% 6% 5% 8% 33% 38% 39% 2% 3% 1% 10% 6% 5% 5% 12% 11% 12% 13% 19% 18% 21% 19% 28% 24% 26% 24% 30% 25% 28% 22% 24% 39% 38% 37% 40% 35% 39% 42% 38% 33% FY16 FY17 FY18 FY16 FY17 FY18 FY16 FY17 FY18 Nor
Slide 19: Consolidated Financial Overview – Trends
Consolidated Financial Overview – Trends 18,000 25% 16,918 16,000 13,829 21.4% 20% 14,000 20.4% Rs mn 14,353 12,000 17.0% 15% 10,000 8,000 11.4% 10% 6,000 8.9% 7.8% 4,000 2,815 3,088 2,893 5% 2,000 1,645 1,230 1,326 0 0% FY16 FY17 FY18 Revenue EBITDA PAT EBITDA Margin PAT Margin © 2018 Granules Indi
Slide 20: Way Forward
Way Forward 19 © 2018 Granules India Limited., All Rights 19 Reserved.
Slide 21: Way Forward
Way Forward Building Profitable Growth Steady Returns Blocks in Place through Execution to the Stakeholders Integrated platform in place that can Expanding portfolio range with Financial discipline to a key focus address the entire value chain from addition of differentiated and intermediates
Slide 22: For further information, please contact
For further information, please contact: Company Investor Relations contact Christensen IR Sumanta Bajpayee Shivangi Bubna Head - Corporate Finance & IR 040-30663572 022-42150210 sumanta.bajpayee@granulesindia.com sbubna@christensenir.com 532482 GRANULES GRAN:IN GRAN:NS © 2018 Granules India Limited